H.C. Wainwright has reiterated its Buy rating on argenx, a Dutch biopharmaceutical company, maintaining a price target of $940 per share. The reaffirmation comes as the firm's lead drug, Vyvgart (efgartigimod), continues to show promise in treating generalised myasthenia gravis and other autoimmune conditions. Argenx shares have climbed approximately 18% year-to-date, outperforming broader biotech indices.
The analyst note highlights argenx's robust pipeline, including ongoing trials for chronic inflammatory demyelinating polyneuropathy (CIDP) and primary Sjögren's syndrome. H.C. Wainwright believes the company's FcRn inhibitor platform could generate significant revenue growth, with Vyvgart already approved in the US and Europe. The $940 target implies a potential upside of over 30% from current levels.
For UK investors, argenx is listed on the Nasdaq and is not a FTSE 100 constituent, but it is held by several London-based investment trusts and pension funds with exposure to global healthcare. The biotech sector has been volatile this year, with the FTSE All-Share Pharmaceuticals & Biotechnology index down 2% over the past month. However, argenx's strong performance has made it a standout in the sector.
Analyst commentary from H.C. Wainwright suggests that argenx's valuation remains attractive relative to its growth prospects. 'We see a clear path to blockbuster sales for Vyvgart and its follow-on indications,' the note stated. 'The company's cash position and disciplined spending provide a buffer against market headwinds.'
The broader market context shows that the FTSE 100 closed at 7,624 points on Friday, down 0.3% on the week, while the Nasdaq Composite gained 1.2% on optimism around rate cuts. Argenx's stock movement reflects a broader appetite for high-growth biotech names among institutional investors. Source: H.C. Wainwright research note.